Crohn's, Eli Lilly and inflammatory bowel disease

FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment
Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.
FDA approves Omvoh for moderately to severely active Crohn's disease
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult population.
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment
Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.
Lilly’s Omvoh approved by FDA for Crohn’s
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.
BioSpace1d
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
Pharm Exec1d
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...
Eli Lilly stock target cut, retains Buy rating on growth potential
Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...